Selank

What Is Selank?

Selank is a synthetic heptapeptide derived from tuftsin, an endogenous immunomodulatory peptide. It was developed in Russia as an investigational neuropeptide with anxiolytic, nootropic, and immunoregulatory properties. Unlike conventional benzodiazepines, Selank does not cause sedation or dependence, making it an attractive candidate for research into stress‑related and cognitive disorders.

Mechanism of Action

Selank modulates neurotransmission primarily through the GABAergic system, enhancing inhibitory signaling and reducing neuronal hyperexcitability. It also influences serotonergic pathways, contributing to mood stabilization and anxiolytic effects. Additionally, Selank has been shown to regulate expression of brain‑derived neurotrophic factor (BDNF), supporting synaptic plasticity and cognitive enhancement. Its immunomodulatory activity stems from its tuftsin origin, with evidence of cytokine regulation and improved immune resilience under stress.

Research & Clinical Data

Preclinical and limited clinical studies suggest Selank’s efficacy in reducing anxiety, improving memory, and stabilizing mood. It has been investigated for generalized anxiety disorder, depression, and cognitive decline. Comparative studies highlight its favorable safety profile, with minimal side effects and no evidence of dependence. Selank remains investigational outside Russia, where it has been approved for limited therapeutic use. Regulatory approval in Western countries has not been established.

Purity & Quality

Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved.

Classification & Handling Class: Synthetic heptapeptide | Source: Tuftsin analog | Administration: Intranasal or parenteral (investigational) | Storage: 2–8°C refrigerated, protect from light | Regulatory: Approved in Russia, investigational elsewhere